Mutations in TP53 increase the risk of SOX2 copy number alterations and silencing of TP53 reduces SOX2 expression in non-small cell lung cancer

详细信息    查看全文

• 作者：Johanna Samulin Erdem ; Vidar Skaug ; Per Bakke ; Amund Gulsvik ; Aage Haugen…
• 关键词：SRY (sex determining region Y) ; box 2 ; NSCLC ; TP53 mutation ; Copy number alteration ; Hsa ; miR ; 14
• 刊名：BMC Cancer
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：16
• 期：1
• 全文大小：825 KB
• 参考文献：1.Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMed CrossRef
  2.Staaf J, Isaksson S, Karlsson A, Jonsson M, Johansson L, Jonsson P, et al. Landscape of somatic allelic imbalances and copy number alterations in human lung carcinoma. Int J Cancer. 2013;132:2020–31.PubMed CrossRef
  3.Seo JS, Ju YS, Lee WC, Shin JY, Lee JK, Bleazard T, et al. The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res. 2012;22:2109–19.PubMed PubMedCentral CrossRef
  4.Iwakawa R, Takenaka M, Kohno T, Shimada Y, Totoki Y, Shibata T, Tsuta K, Nishikawa R, Noguchi M, Sato-Otsubo A et al. Genome-wide identification of genes with amplification and/or fusion in small cell lung cancer. Genes Chromosomes Cancer. 2013;52:802-16.
  5.Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489:519–25.CrossRef
  6.Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer. 2009;9:95–107.PubMed CrossRef
  7.Henkler F, Stolpmann K, Luch A. Exposure to polycyclic aromatic hydrocarbons: bulky DNA adducts and cellular responses. EXS. 2012;101:107–31.PubMed
  8.Llanos S, Efeyan A, Monsech J, Dominguez O, Serrano M. A High-Throughput Loss-of-Function Screening Identifies Novel p53 Regulators. Cell Cycle. 2006;5:1880–5.PubMed CrossRef
  9.Dillon LW, Burrow AA, Wang Y-H. DNA Instability at Chromosomal Fragile Sites in Cancer. Current Genomics. 2010;11:326–37.PubMed PubMedCentral CrossRef
  10.Dehan E, Ben-Dor A, Liao W, Lipson D, Frimer H, Rienstein S, et al. Chromosomal aberrations and gene expression profiles in non-small cell lung cancer. Lung Cancer. 2007;56:175–84.PubMed CrossRef
  11.Balsara BR, Testa JR. Chromosomal imbalances in human lung cancer. Oncogene. 2002;21:6877–83.PubMed CrossRef
  12.Gontan C, de Munck A, Vermeij M, Grosveld F, Tibboel D, Rottier R. Sox2 is important for two crucial processes in lung development: branching morphogenesis and epithelial cell differentiation. Dev Biol. 2008;317:296–309.PubMed CrossRef
  13.Yuan P, Kadara H, Behrens C, Tang X, Woods D, Solis LM, et al. Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung. PLoS One. 2010;5:e9112.PubMed PubMedCentral CrossRef
  14.Velcheti V, Schalper K, Yao X, Cheng H, Kocoglu M, Dhodapkar K, et al. High SOX2 levels predict better outcome in non-small cell lung carcinomas. PLoS One. 2013;8:e61427.PubMed PubMedCentral CrossRef
  15.Wilbertz T, Wagner P, Petersen K, Stiedl AC, Scheble VJ, Maier S, et al. SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer. Mod Pathol. 2011;24:944–53.PubMed CrossRef
  16.Sholl LM, Long KB, Hornick JL. Sox2 expression in pulmonary non-small cell and neuroendocrine carcinomas. Appl Immunohistochem Mol Morphol. 2010;18:55–61.PubMed CrossRef
  17.Li M, He Y, Dubois W, Wu X, Shi J, Huang J. Distinct regulatory mechanisms and functions for p53-activated and p53-repressed DNA damage response genes in embryonic stem cells. Mol Cell. 2012;46:30–42.PubMed PubMedCentral CrossRef
  18.Chen K, Wu K, Cai S, Zhang W, Zhou J, Wang J, et al. Dachshund Binds p53 to Block the Growth of Lung Adenocarcinoma Cells. Cancer Res. 2013.
  19.Jain AK, Allton K, Iacovino M, Mahen E, Milczarek RJ, Zwaka TP, et al. p53 regulates cell cycle and microRNAs to promote differentiation of human embryonic stem cells. PLoS Biol. 2012;10:e1001268.PubMed PubMedCentral CrossRef
  20.Avgeris M, Stravodimos K, Fragoulis EG, Scorilas A. The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients. Br J Cancer. 2013;108:2573–81.PubMed PubMedCentral CrossRef
  21.Sachdeva M, Zhu S, Wu F, Wu H, Walia V, Kumar S, et al. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci U S A. 2009;106:3207–12.PubMed PubMedCentral CrossRef
  22.Campayo M, Navarro A, Vinolas N, Diaz T, Tejero R, Gimferrer JM, et al. Low miR-145 and high miR-367 are associated with unfavourable prognosis in resected nonsmall cell lung cancer. Eur Respir J. 2013;41:1172–8.PubMed CrossRef
  23.D'Haene B, Vandesompele J, Hellemans J. Accurate and objective copy number profiling using real-time quantitative PCR. Methods. 2010;50:262–70.PubMed CrossRef
  24.Weaver S, Dube S, Mir A, Qin J, Sun G, Ramakrishnan R, et al. Taking qPCR to a higher level: Analysis of CNV reveals the power of high throughput qPCR to enhance quantitative resolution. Methods. 2010;50:271–6.PubMed CrossRef
  25.Lind H, Ekstrom PO, Ryberg D, Skaug V, Andreassen T, Stangeland L, et al. Frequency of TP53 mutations in relation to Arg72Pro genotypes in non small cell lung cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:2077–81.PubMed CrossRef
  26.Kristensen AT, Bjorheim J, Ekstrom PO. Detection of mutations in exon 8 of TP53 by temperature gradient 96-capillary array electrophoresis. Biotechniques. 2002;33:650–3.PubMed
  27.Zienolddiny S, Skaug V, Landvik NE, Ryberg D, Phillips DH, Houlston R, et al. The TERT-CLPTM1L lung cancer susceptibility variant associates with higher DNA adduct formation in the lung. Carcinogenesis. 2009;30:1368–71.PubMed CrossRef
  28.Ge N, Lin HX, Xiao XS, Guo L, Xu HM, Wang X, et al. Prognostic significance of Oct4 and Sox2 expression in hypopharyngeal squamous cell carcinoma. J Transl Med. 2010;8:94.PubMed PubMedCentral CrossRef
  29.Huang P, Qiu J, Li B, Hong J, Lu C, Wang L, et al. Role of Sox2 and Oct4 in predicting survival of hepatocellular carcinoma patients after hepatectomy. Clin Biochem. 2011;44:582–9.PubMed CrossRef
  30.Matsuoka J, Yashiro M, Sakurai K, Kubo N, Tanaka H, Muguruma K, et al. Role of the stemness factors sox2, oct3/4, and nanog in gastric carcinoma. J Surg Res. 2012;174:130–5.PubMed CrossRef
  31.Saigusa S, Mohri Y, Ohi M, Toiyama Y, Ishino Y, Okugawa Y, et al. Podoplanin and SOX2 expression in esophageal squamous cell carcinoma after neoadjuvant chemo-radiotherapy. Oncol Rep. 2011;26:1069–74.PubMed
  32.Wang X, Liang Y, Chen Q, Xu HM, Ge N, Luo RZ, et al. Prognostic significance of SOX2 expression in nasopharyngeal carcinoma. Cancer Invest. 2012;30:79–85.PubMed CrossRef
  33.Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG, et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet. 2009;41:1238–42.PubMed PubMedCentral CrossRef
  34.Cai YR, Zhang HQ, Zhang ZD, Mu J, Li ZH. Detection of MET and SOX2 amplification by quantitative real-time PCR in non-small cell lung carcinoma. Oncol Lett. 2011;2:257–64.PubMed PubMedCentral CrossRef
  35.Hussenet T, Dali S, Exinger J, Monga B, Jost B, Dembele D, et al. SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas. PLoS One. 2010;5:e8960.PubMed PubMedCentral CrossRef
  36.Sasaki H, Yokota K, Hikosaka Y, Moriyama S, Yano M, Fujii Y. Increased Sox2 copy number in lung squamous cell carcinomas. Exp Ther Med. 2012;3:44–8.PubMed PubMedCentral
  37.Nakatsugawa M, Takahashi A, Hirohashi Y, Torigoe T, Inoda S, Murase M, et al. SOX2 is overexpressed in stem-like cells of human lung adenocarcinoma and augments the tumorigenicity. Lab Invest. 2011;91:1796–804.PubMed CrossRef
  38.Chen S, Xu Y, Chen Y, Li X, Mou W, Wang L, et al. SOX2 gene regulates the transcriptional network of oncogenes and affects tumorigenesis of human lung cancer cells. PLoS One. 2012;7:e36326.PubMed PubMedCentral CrossRef
  39.Xiang R, Liao D, Cheng T, Zhou H, Shi Q, Chuang TS, et al. Downregulation of transcription factor SOX2 in cancer stem cells suppresses growth and metastasis of lung cancer. Br J Cancer. 2011;104:1410–7.PubMed PubMedCentral CrossRef
  40.Singh S, Trevino J, Bora-Singhal N, Coppola D, Haura E, Altiok S, et al. EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancer. Mol Cancer. 2012;11:73.PubMed PubMedCentral CrossRef
  41.McCaughan F, Pole JC, Bankier AT, Konfortov BA, Carroll B, Falzon M, et al. Progressive 3q amplification consistently targets SOX2 in preinvasive squamous lung cancer. Am J Respir Crit Care Med. 2010;182:83–91.PubMed PubMedCentral CrossRef
  42.Lu Y, Futtner C, Rock JR, Xu X, Whitworth W, Hogan BL, et al. Evidence that SOX2 overexpression is oncogenic in the lung. PLoS One. 2010;5:e11022.PubMed PubMedCentral CrossRef
  43.Brcic L, Sherer CK, Shuai Y, Hornick JL, Chirieac LR, Dacic S. Morphologic and Clinicopathologic Features of Lung Squamous Cell Carcinomas Expressing Sox2. Am J Clin Pathol. 2012;138:712–8.PubMed CrossRef
  44.Sholl LM, Barletta JA, Yeap BY, Chirieac LR, Hornick JL. Sox2 protein expression is an independent poor prognostic indicator in stage I lung adenocarcinoma. Am J Surg Pathol. 2010;34:1193–8.PubMed PubMedCentral CrossRef
  45.Hussenet T, du Manoir S. SOX2 in squamous cell carcinoma: amplifying a pleiotropic oncogene along carcinogenesis. Cell Cycle. 2010;9:1480–6.PubMed CrossRef
  46.Toschi L, Finocchiaro G, Nguyen TT, Skokan MC, Giordano L, Gianoncelli L, et al. Increased SOX2 Gene Copy Number Is Associated with FGFR1 and PIK3CA Gene Gain in Non-Small Cell Lung Cancer and Predicts Improved Survival in Early Stage Disease. PLoS One. 2014;9:e95303.PubMed PubMedCentral CrossRef
  47.Chen Y, Huang Y, Huang Y, Chen J, Wang S, Zhou J. The prognostic value of SOX2 expression in non-small cell lung cancer: a meta-analysis. PLoS One. 2013;8:e71140.PubMed PubMedCentral CrossRef
  48.Shlien A, Tabori U, Marshall CR, Pienkowska M, Feuk L, Novokmet A, et al. Excessive genomic DNA copy number variation in the Li-Fraumeni cancer predisposition syndrome. Proc Natl Acad Sci U S A. 2008;105:11264–9.PubMed PubMedCentral CrossRef
  49.Husgafvel-Pursiainen K, Boffetta P, Kannio A, Nyberg F, Pershagen G, Mukeria A, et al. p53 mutations and exposure to environmental tobacco smoke in a multicenter study on lung cancer. Cancer Res. 2000;60:2906–11.PubMed
  50.Takagi Y, Osada H, Kuroishi T, Mitsudomi T, Kondo M, Niimi T, et al. p53 mutations in non-small-cell lung cancers occurring in individuals without a past history of active smoking. Br J Cancer. 1998;77:1568–72.PubMed PubMedCentral CrossRef
  51.Vahakangas KH, Bennett WP, Castren K, Welsh JA, Khan MA, Blomeke B, et al. p53 and K-ras mutations in lung cancers from former and never-smoking women. Cancer Res. 2001;61:4350–6.PubMed
  52.MacNeil AJ, Jiao S-C, McEachern LA, Yang YJ, Dennis A, Yu H, et al. MAPK Kinase 3 Is a Tumor Suppressor with Reduced Copy Number in Breast Cancer. Cancer Res. 2014;74:162–72.PubMed CrossRef
  53.Fischer U, Heckel D, Michel A, Janka M, Hulsebos T, Meese E. Cloning of a Novel Transcription Factor-Like Gene Amplified in Human Glioma Including Astrocytoma Grade I. Hum Mol Genet. 1997;6:1817–22.PubMed CrossRef
  54.Valinezhad Orang A, Safaralizadeh R, Kazemzadeh-Bavili M. Mechanisms of miRNA-Mediated Gene Regulation from Common Downregulation to mRNA-Specific Upregulation. Int J Genomics. 2014;2014:970607.PubMed PubMedCentral CrossRef
  55.Cordes KR, Sheehy NT, White M, Berry E, Morton SU, Muth AN, et al. miR-145 and miR-143 Regulate Smooth Muscle Cell Fate Decisions. Nature. 2009;460:705–10.PubMed PubMedCentral
  56.Li E, Zhang J, Yuan T, Ma B. miR-145 inhibits osteosarcoma cells proliferation and invasion by targeting ROCK1. Tumor Biology. 2014;35:7645–50.PubMed CrossRef
  57.Park JH, Roeder RG. GAS41 is required for repression of the p53 tumor suppressor pathway during normal cellular proliferation. Mol Cell Biol. 2006;26:4006–16.PubMed PubMedCentral CrossRef
  58.Han J, Sun P. The pathways to tumor suppression via route p38. Trends Biochem Sci. 2007;32:364–71.PubMed CrossRef
  
• 作者单位：Johanna Samulin Erdem (1)
  Vidar Skaug (1)
  Per Bakke (2)
  Amund Gulsvik (2)
  Aage Haugen (1)
  Shanbeh Zienolddiny (1)
  
  1. Department of Biological and Chemical Work Environment, National Institute of Occupational Health, PO Box 8149 Dep,, N-0033, Oslo, Norway
  2. Department of Clinical Science, University of Bergen, Bergen, Norway
  
• 刊物主题：Cancer Research; Oncology; Stem Cells; Animal Models; Internal Medicine;
• 出版者：BioMed Central
• ISSN：1471-2407

文摘

Background Amplifications of the transcription factor, SRY (sex determining region Y)-box 2 (SOX2), are common in non-small cell lung cancer (NSCLC). SOX2 signaling is important in maintaining the stem cell-like phenotype of cancer cells and contributes to the pathogenesis of lung cancer. TP53 is known to inhibit gene amplifications and to repress many stem cell-associated genes following DNA damage. The aim of this study was to investigate if TP53 mutational status affected SOX2 copy number variation and gene expression in early-stage NSCLC patients; moreover, to assess if TP53 regulates SOX2 expression in human lung cancer cells.